Public release date: 27-Feb-2013 [ | E-mail | Share ] Contact: George Hunka ghunka@aftau.org 212-742-9070 American Friends of Tel Aviv University Tel Aviv For the estimated 250 million people worldwide who suffer from rare diseases, there is little hope for diagnosis or treatment. Because each individual disease impacts so few people, hardly any funding is allocated to research, leaving many without medical options. The US-based non-profit organization Rare Genomics Institute (RGI) is working to address this problem by "crowd-funding" allowing people to donate on the Internet towards genetic testing for individual children who are struggling with a rare disease. Now, thanks to Dr. Noam Shomron of Tel Aviv University's Sackler Faculty of Medicine, RGI's vital mission has come to Israel the first international branch of the organization. Its online home is http://raregenomics.org/world_Israel.php, and it has launched its first appeal for two Israeli children at http://raregenomics.org/donors.php. Based at the TAU-affiliated Sourasky Medical Center and Rabin Medical Center, RGI-Israel will help families with children impacted by rare genetic diseases find support and care through advanced genetic testing. The Israeli branch is run in collaboration with three of Israel's top geneticists, Drs. Lina Basel, Shay Ben-Shachar, and Hagit Baris. The services that the … Continue reading →

Biblioteca Ambrosiana via LGPN This codex of Homer's "Iliad" was produced in the late fifth century or early sixth century. By Joel N. Shurkin Inside Science News Service Scientists who decode the genetic history of humans by tracking how genes mutate have applied the same technique to one of the Western world's most ancient and celebrated texts to uncover the date it was first written. The text is Homer's "Iliad," and Homer if there was such a person probably wrote it in 762 B.C., give or take 50 years, the researchers found. The "Iliad" tells the story of the Trojan War if there was such a war with Greeks battling Trojans. The researchers accept the received orthodoxy that a war happened and someone named Homer wrote about it, said Mark Pagel, an evolutionary theorist at the University of Reading in England. His collaborators include Eric Altschuler, a geneticist at the University of Medicine and Dentistry of New Jersey, in Newark, and Andreea S. Calude, a linguist also at Reading and the Santa Fe Institute in New Mexico. They worked from the standard text of the epic poem. The date they came up with fits the time most scholars think the … Continue reading →

Dr. Mahajan's Interview on Hitguj Dr Mahajan's Interview about Stem Cell Treatment on Marathi News Chanel. explaining about Stem Cell treatment the usefulness facts about stem cell treatment. By: StemRx BioScience … Continue reading →

Part 15, after stem cell treatment, Big drop in energy, 20fev2013 My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it's in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video. By: Kina Diamond … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nanobiosym, a leading nanotechnology firm, has announced that M.I.T. professor Dr. Robert Langer, winner of the Lemelson-M.I.T. Innovation Prize, has joined the companys Scientific Advisory Board. Dr. Langer was recently awarded the National Medal of Innovation and Technology by President Obama and has served as chairman of the FDAs highest advisory board. Nanobiosym creates and commercializes breakthrough technologies at the nexus of physics, biomedicine and nanotechnology. Nanobiosyms product platform, Gene-RADAR, is a mobile device that detects DNA/RNA biomarkers in real time, enabling individuals to personalize their diagnosis and monitor their response to treatment. I am delighted to welcome Dr. Langer to our team, said Nanobiosym Chairman and CEO, Dr. Anita Goel, a Harvard-M.I.T. physicist-physician and internationally renowned nanotechnology scientist and entrepreneur. Dr. Langer has been pioneering the precision delivery of drugs and novel therapeutics and we at Nanobiosym have been developing mobile platforms that quantify molecular fingerprints in real time. In collaboration with forward-thinking pharmaceutical companies, we are developing companion nanodiagnostics that will enable novel medicines and therapies to reach patients faster. Our goal is to make medicine less toxic, more precise, more affordable and more effective by personalizing it for each individual. We call this Personalized … Continue reading →

Bangalore, Feb. 27 -- In a major scientific breakthrough, Indian researchers have collaborated to develop peptide nanoparticles that may be used as vehicles for targeted drug delivery for tumours. The study - Modified dipeptide based nanoparticles: Vehicles for targetted tumour drug delivery published in the journal Nanomedicine says that different nanoparticles have been investigated to deliver chemotherapeutic agents but complex synthetic procedures and biocompatibility issues raise concerns in developing them for safe human usage. The research was done collectively by the scientists at the International Center for Genetic Engineering and Biotechnology (ICGEB), Institute of Nuclear Medicine and Allied Sciences and National Center for Cell Science, Pune. "Conventional treatment methods such as chemotherapy and radiation therapy are not fully safe and free from side effects despite all the progress made in this area. Peptides-based nanoparticles are attracting attention of the scientific community due to their wide potential and have also been investigated to deliver chemotherapeutic agents. The present research may prove a milestone in the development of more stable, non-toxic simple peptide-based nanostructure for effective drug delivery system for cancer," Prof V S Chauhan, director ICGEB and one of the authors of the study told HT. The in-vivo studies for evaluating … Continue reading →

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the company was recently featured on national and local news, as well as Fox News. Rasheda Ali, a member of BrainStorms advisory board and revered author and daughter of renowned boxer Muhammad Ali, discussed BrainStorms promising ALS clinical trials last week on NBC NY and Current TVs Viewpoint. She was also interviewed on Fox News Geraldo at Large and Neil Cavuto shows. In her various interviews, Ms. Ali stated that BrainStorms Phase I/II ALS clinical trial results with its NurOwn stem cell candidate exceeded scientists expectations, surpassing the goal of confirming safety by also showing initial signs of clinical improvement. She also discussed BrainStorms recent acceleration to a Phase IIa trial by the Israeli Ministry of Health. Ms. Alis interviews can be viewed at the following links: NBC NY: http://bit.ly/Xam0rG. Current TV Viewpoint: http://bit.ly/13VDZRY About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop … Continue reading →